Biocon Biologics Achieves Significant U.S. Market Access for Biosimilar Yesintek
Biocon Biologics has achieved a major milestone by securing multiple U.S. market access agreements for Yesintek, a biosimilar to Stelara, expanding affordable treatment for millions with autoimmune conditions.
